Clay B. Siegall

CIK: 0001167496

Transaction Breakdown

Open Market Buys (P)8 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (5.0%)

Derivative conversions

Awards (A)7 (35.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

IMNM

Immunome Inc.

DirectorOfficer

STTK

Shattuck Labs, Inc.

Director

TRML

Tourmaline Bio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (20 total)

IMNM
Immunome Inc.
Jul 23, 2026
Award(A)
Direct
180K shares-
STTK
Shattuck Labs, Inc.
Jun 9, 2026
Purchase(P)
Direct
62.5K shares at avg. $4.00$250K
STTK
Shattuck Labs, Inc.
May 29, 2026
Award(A)
Stock Option (Right to Buy)
Direct
81K shares-
STTK
Shattuck Labs, Inc.
May 22, 2026
Exercise(M)
Warrants (Right to Buy)
Direct
128.1K shares-
STTK
Shattuck Labs, Inc.
May 22, 2026
Award(A)
Direct
128.1K shares at avg. $1.08$139K
IMNM
Immunome Inc.
Dec 30, 2025
Purchase(P)
Direct
4.7K shares at avg. $21.15$100K
IMNM
Immunome Inc.
Dec 19, 2025
Purchase(P)
Direct
7.3K shares at avg. $20.48$149K
IMNM
Immunome Inc.
Dec 19, 2025
Gift(G)
Direct
200K shares-
IMNM
Immunome Inc.
Dec 18, 2025
Purchase(P)
Direct
46.5K shares at avg. $21.50$1000K
TRML
Tourmaline Bio, Inc.
Oct 28, 2025
Disposition(D)
Employee Stock Option (Right to Buy)
Direct
16.8K shares-
TRML
Tourmaline Bio, Inc.
Oct 28, 2025
Disposition(D)
Employee Stock Option (Right to Buy)
Direct
20K shares-
TRML
Tourmaline Bio, Inc.
Oct 28, 2025
Disposition(D)
Employee Stock Option (Right to Buy)
Direct
15K shares-
STTK
Shattuck Labs, Inc.
Aug 25, 2025
Award(A)
Direct
128.1K shares at avg. $0.87$111K
IMNM
Immunome Inc.
Jul 29, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
800K shares-
STTK
Shattuck Labs, Inc.
Jul 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
33.2K shares-
TRML
Tourmaline Bio, Inc.
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
16.8K shares-
IMNM
Immunome Inc.
Mar 26, 2025
Purchase(P)
Direct
137.1K shares at avg. $7.29$999K
IMNM
Immunome Inc.
Jan 31, 2025
Purchase(P)
Direct
150K shares at avg. $7.75$1.2M
IMNM
Immunome Inc.
Nov 22, 2024
Purchase(P)
Direct
33.9K shares at avg. $9.78$332K
IMNM
Immunome Inc.
Nov 21, 2024
Purchase(P)
Direct
66.1K shares at avg. $9.54$630K

		Type	Shares	Price		Ownership
Jul 23, 2026	IMNM Immunome Inc.	Award(A)	180,000	-	$0	Direct
Jun 9, 2026	STTK Shattuck Labs, Inc.	Purchase(P)	62,500	$4.00	$250,000	Direct
May 29, 2026	STTK Shattuck Labs, Inc.	Award(A) Stock Option (Right to Buy)	81,000	-	-	Direct
May 22, 2026	STTK Shattuck Labs, Inc.	Exercise(M) Warrants (Right to Buy)	128,054	-	-	Direct
May 22, 2026	STTK Shattuck Labs, Inc.	Award(A)	128,054	$1.08	$138,887	Direct
Dec 30, 2025	IMNM Immunome Inc.	Purchase(P)	4,729	$21.15	$100,018	Direct
Dec 19, 2025	IMNM Immunome Inc.	Purchase(P)	7,278	$20.48	$149,053	Direct
Dec 19, 2025	IMNM Immunome Inc.	Gift(G)	200,000	-	-	Direct
Dec 18, 2025	IMNM Immunome Inc.	Purchase(P)	46,511	$21.50	$999,987	Direct
Oct 28, 2025	TRML Tourmaline Bio, Inc.	Disposition(D) Employee Stock Option (Right to Buy)	16,800	-	-	Direct
Oct 28, 2025	TRML Tourmaline Bio, Inc.	Disposition(D) Employee Stock Option (Right to Buy)	20,000	-	-	Direct
Oct 28, 2025	TRML Tourmaline Bio, Inc.	Disposition(D) Employee Stock Option (Right to Buy)	15,000	-	-	Direct
Aug 25, 2025	STTK Shattuck Labs, Inc.	Award(A)	128,054	$0.87	$111,112	Direct
Jul 29, 2025	IMNM Immunome Inc.	Award(A) Employee Stock Option (right to buy)	800,000	-	-	Direct
Jul 14, 2025	STTK Shattuck Labs, Inc.	Award(A) Stock Option (Right to Buy)	33,150	-	-	Direct
Jun 4, 2025	TRML Tourmaline Bio, Inc.	Award(A) Stock Option (Right to Buy)	16,800	-	-	Direct
Mar 26, 2025	IMNM Immunome Inc.	Purchase(P)	137,100	$7.29	$999,459	Direct
Jan 31, 2025	IMNM Immunome Inc.	Purchase(P)	150,000	$7.75	$1,162,500	Direct
Nov 22, 2024	IMNM Immunome Inc.	Purchase(P)	33,943	$9.78	$331,918	Direct
Nov 21, 2024	IMNM Immunome Inc.	Purchase(P)	66,057	$9.54	$630,263	Direct

1-20 of 20 transactions

About SIEGALL CLAY B

SIEGALL CLAY B (SEC CIK 0001167496) files insider reports with the SEC as President and CEO of Immunome Inc. (IMNM), Director of Shattuck Labs, Inc. (STTK) and Director of Tourmaline Bio, Inc. (TRML).

Signal8 holds 15 ownership filings by SIEGALL CLAY B, all Form 4s, filed between Nov 25, 2024 and Jul 27, 2026. Those filings report 20 transactions, from Nov 21, 2024 to Jul 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SIEGALL CLAY B's filings is in BOTHELL, WA.

Recent filings by SIEGALL CLAY B

Jul 23, 2026: Grant or award of IMNM shares (Form 4, code A).
Jun 9, 2026: Open-market purchase of STTK shares (Form 4, code P).
May 29, 2026: Grant or award of STTK derivative securities (Form 4, code A).
May 22, 2026: Option exercise of STTK derivative securities (Form 4, code M).
May 22, 2026: Grant or award of STTK shares (Form 4, code A).

Other insiders filing for Immunome Inc. (IMNM)

Higgins Jack, Chief Scientific Officer
Barchas Isaac, Director
Horn Kinney, CHIEF BUSINESS OFFICER
Tsai Philip, Chief Technical Officer
Stoneman Sandra G., CHIEF LEGAL OFFICER & GC
Rosett Max, Chief Financial Officer

How to read Form 4 transaction codes